STUDY PROTOCOL

“AMR Dialogues”: a public engagement initiative to shape policies and solutions on antimicrobial resistance (AMR) in Thailand [version 1; peer review: 1 approved]

Tassawan Poomchaichote¹, Anne Osterrieder¹,², Ravikanya Prapharsavat¹, Bhensri Naemiratch¹, Supanat Ruangkajorn¹, Chaiwat Thirapantu³, Karnjariya Sukrung³, Niyada Kiatyng-Angsulee⁴, Nithima Sumpradit⁵, Sirima Punnin⁵, Direk Limmathurotsakul¹,²,⁶, Phaik Yeong Cheah¹,²

¹Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
²Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
³Civicnet Foundation, Bangkok, Thailand
⁴Drug System Monitoring and Development Centre, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
⁵Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand
⁶Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Abstract

Background: The use of antimicrobials in Thailand has been reported as one of the highest in the world in both the human and animal sectors. The objectives of this project are: (1) to improve understanding of the issue of antimicrobial resistance (AMR) among adult Thai communities and (2) to drive change through the national AMR policy to include context-specific and locally-driven solutions.

Methods: The project contains two components conducted in parallel: the “AMR Dialogues” public engagement project and the embedded evaluation of the project. We will bring together AMR stakeholders and members of the public through a series of conversation events to co-create an AMR stakeholder map, engagement strategy, and context-specific solutions to reduce the burden of AMR. There will be a combination of regional in-person events ('regional conversations') and national online events ('national conversations') with members of the public. The conversations will follow this sequence: introduce and explore issues related to AMR, brainstorm solutions and finally propose promising/feasible solutions to take forward. Evaluation of the project will be conducted to assess if the AMR Dialogues objectives have been achieved using feedback forms and qualitative methods.

Ethics: Approval of the evaluation component of the project has been obtained from the ethics committee of the Thailand Institute for the Development of Human Subject Protection (IHRP2021059) and the
Oxford University Tropical Research Ethics Committee (OxTREC S29-21).

**Dissemination:** The results of these conversation events will inform the next Thailand National Strategic Plan on AMR. The learning and outcomes will be disseminated to AMR policy makers, academic audiences, and participants of all the conversation events.

**Thaiclinicaltrials.org registration:** TCTR20210528003 (28/05/2021)

**Keywords**
antimicrobial resistance, Thailand, antibiotics, responsive dialogues, public engagement

This article is included in the Mahidol Oxford Tropical Medicine Research Unit (MORU) gateway.
Introduction
Antimicrobial resistance (AMR) is the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to stop antimicrobial drugs (such as antibiotics, antivirals, antifungal drugs and antiparasitic drugs) from working against them. It has been estimated that globally there will be around 700,000 deaths each year caused by AMR bacterial infections. The human and economic cost of AMR is estimated to account for 10 million deaths a year and economic losses of US$100 trillion globally by 2050. It is projected that a disproportionate number of AMR-related deaths are likely to occur in Asia because of the high burden of infectious diseases, poor monitoring and regulation of antimicrobials, high population density and growth, and antibiotics are sold widely over-the-counter often without a prescription. South-East Asia has been characterised as a region ‘at high risk of the emergence and spread of antibiotic resistance in humans’. In Thailand, there were an estimated 19,122 deaths in 2010 attributable to multidrug resistant hospital-acquired infections.

Thailand’s healthcare system is made up of a combination of a network of public health facilities and private healthcare providers and overseen by the Ministry of Public Health. Universal health coverage has been in place since 2002. In rural and poorer areas, primary healthcare is primarily provided by the public healthcare system, whereas in urban and more affluent areas, private providers play a larger role. In Thailand, by law, most antimicrobials can be dispensed by licensed pharmacists at pharmacies without a prescription. Some antimicrobials are listed prescription drugs. Nevertheless, some antibiotics are sold illegally at informal stores.

The Thai general public have a limited understanding of AMR, which is partly attributable to the challenge of communicating technical concepts of AMR in Thai language. Antibiotics are often confused with anti-inflammatory drugs in Thailand, and have become a quick fix for care, productivity, hygiene and inequity. Thailand has one of the highest antibiotic use in both human and animal sectors among countries that have published official data on national antibiotic consumption. In 2017, Thailand used a total of 8,757 tons of antimicrobials, and in 2018, 10,133 tons.

For decades, Thailand had taken actions to address AMR such as establishing the National AMR Surveillance Center, Thailand (NARST) in 1997, and launching the Antibiotic Smart Use programme focusing on changing prescribing practices made by healthcare providers in 2007.

In 2016, the Thailand National Strategic Plan on AMR (NSP-AMR), a 5-year plan from 2017 to 2021, was endorsed by the Cabinet as the first national plan to address the problem of AMR in Thailand. The NSP-AMR comprises of six strategies. The “AMR Dialogues” project will integrate with the NSP-AMR’s Strategy 5 (public knowledge and awareness of appropriate use of antimicrobials) and provide input into Strategy 6 (governance mechanisms to develop and sustain AMR-related actions). It will inform the NSP-AMR process beyond 2021.

The Thailand “AMR Dialogues” project uses the Wellcome Trust’s toolkit “Responsive Dialogues (RDs) on Drug Resistant Infections”, which suggests a format for holding these Dialogues (see Methods). This project builds on our previous engagement work around AMR such as “AMR Dictionary”, “antibiotic footprint”, and art and theatre projects around AMR in Thailand and Southeast Asia, and complements existing campaigns such as the annual Antimicrobial Awareness Day/Week held since 2013.

Previous and existing AMR campaigns have primarily focused on raising awareness through education and events. The current project focuses on engagement through a series of dialogues with different members of the community to generate solutions that are grounded in local realities and embrace ideas and views from the public. The project will bring together AMR stakeholders and members of the public to co-create an AMR stakeholder map, engagement strategy, and context-specific solutions with the aim of reducing the burden of AMR in Thailand.

The main objectives of this project are:
1) to improve understanding of the issue of AMR among adult Thai communities and
2) to drive change through the national AMR policy to include context-specific and locally-driven solutions.

The intended long-term impacts of the project include empowerment of communities through co-creation of locally relevant solutions to AMR; and improved policies for reducing the burden of AMR across Thailand.

Protocol
This protocol has been registered at Thaiclinicaltrials.org on the 28th May 2021 (TCTR20210528003).

Part 1: AMR Dialogues
There will be three phases in the project involving a series of dialogues or “conversations” held over 18 months.

All conversations will be led by members of the project team who have had experience and training in public engagement and facilitation. All sessions will be audio-recorded to facilitate note taking.

Phase 1: Two planning conversations. The planning conversations are events comprising one or two-day meetings and held in Bangkok, Thailand at a conference venue led by members of the project team (PYC and NKA, female; CT, male). Approximately 20–25 attendees of all genders will participate in the conversations. From our experience facilitating workshops, 20–25 people are ideal to ensure that the sessions are small enough to be interactive and large enough to have a wide range of views. With this number we can also have breakout groups. The attendees will include AMR national policy makers, AMR researchers and experts, healthcare providers and non-governmental organization (NGO) representatives. The same participants will attend both meetings. Diverse stakeholders
will be invited through professional networks, many of whom would have previously worked with project team members in AMR related or other healthcare projects.

The aim of the planning conversations is to understand the AMR ecosystem in Thailand, narrow down AMR focus, design the structure, and identify participants for the community conversations.

**Phase II: Seven community conversations.** There are two types of community conversations: regional conversations and national conversations that will be conducted in parallel. By holding these two types of events, we hope to be as inclusive as possible and maximise the chance of having a diverse audience.

Regional conversations will be led by CT (male) and TP (female) and national conversations will be led by TP (female), RP (female) and SR (male).

**Participant selection criteria for community conversations:**

1. Participants who have the capacity and means to drive and engage people in the community such as youth leaders. This will be a subjective assessment based on participants involvement in other AMR or health-related projects
2. Participants who have the commitment and are influential in the community such as religious leaders, teachers, village elders
3. Participants who could have an impact on behaviour change in antimicrobials use such as local healthcare workers e.g. nurses, pharmacists, doctors, village health volunteers
4. Participants who are familiar with the local context, lifestyles and culture of each region e.g. in the Northeastern region, we will invite people who live in slums, in the Central will invite people from labour camps, dormitory or migrant workers
5. Participants who have leadership characteristics such as community leaders. This assessment will be based on their involvement in community groups and committees.
6. Participants who are potential “solution experts” e.g. those who work in mass media, media influencers, science communication specialists, radio broadcasters, reporters
7. Participants who are longterm or frequent users of antimicrobials e.g. for treatment of tuberculosis, acne
8. Participants who are users of antimicrobials in the animal sector such as farmers
9. Participants from minority groups e.g. LGBTQ (lesbian, gay, bisexual, transgender and queer), disabled, hilltribes
10. Participants from different age groups, social groups, and educational levels
11. Participants with different occupations

The regional conversations focus on regional issues and will be attended in person by local residents, while the online national conversations focus on national issues and will be attended by people from all over the country. We hope that with a combination of these two types of conversations, we will include voices of all of the above participant groups.

Regional conversations will be in-person four-day sessions and held in four regions in Thailand (north, northeast, south and central) at conference venues/community halls. Approximately 20–25 attendees will attend the conversations from each region (total of 80–100). From our experience facilitating workshops, 20–25 people are ideal to ensure that the sessions are small enough to be interactive and large enough to have a wide range of views. We also plan to have two virtual breakout rooms of 10–12/13 each. Each regional conversation will follow the following sequence as detailed in the Wellcome Trust’s ‘Responsive Dialogues’ toolkit: introduce and explore issues related to AMR in the region, brainstorm local solutions and finally choose promising/feasible solutions to take forward.

National conversations will consist of three online conversations and held three hours once a month for three months consecutively. Approximately 20–25 attendees will participate in the conversations. The same participants will be asked to attend all three sessions. Similar to the regional conversations, the online national conversations will follow the following sequence as detailed in the Wellcome Trust’s ‘Responsive Dialogues’ toolkit. The first session will introduce and explore issues related to AMR in the region, the second session will involve brainstorming locals solutions and the third session with involve participants proposing promising/feasible solutions to take forward.

**Phase III: Two final conversations.** The events will be one or two day meetings and held in Bangkok, Thailand at a conference venue. Approximately 20–25 attendees will participate in the conversations. The attendees will include AMR national policy makers, AMR researchers and experts, healthcare providers, non-governmental organizations (NGO), and communication and “solution experts”.

In these conversations, findings from the community conversations will be fed back to stakeholders. Depending on what solutions have been proposed during the community conversations, we will invite the relevant “solution experts”. For example, if a social media campaign has been suggested, we will invite social media experts.

Participants for all the conversations will be invited in writing by the project team with details of the project.
Part 2: Evaluation
Evaluation will be conducted in parallel with all ‘AMR Dialogues’ events (planning conversations, regional conversations, national conversations, final conversations) to assess if the AMR dialogues objectives have been achieved.

Data collection strategies for evaluation and sample size. Feedback forms will be used at the end of each conversation event. Participants will be asked to complete a short feedback either on paper or online.

Daily reflections and feedback in writing will be used for events that run over multiple days (i.e regional conversations). An informal dialogue session will be set up at the end of each day which will take a maximum of 30 minutes. Participants will share their active observations and feedback on key issues. The daily reflection would help the event facilitators to adjust the conversation process better the next day. Participants are requested to write their reflections on a set of questions which aim to assess 1) their understanding or increased knowledge on AMR, 2) their level of awareness of AMR, and 3) their actions or solutions they think they would and could do regarding AMR. The writing activity will take maximum 30 minutes.

Focus group discussions (FGDs) will be used for events that run over multiple days (i.e. regional conversations). On the last day of event, participants who express their interest in joining the evaluation will be invited to share their active observations and feedbacks on key issues. We expect to run four FGDs of between 6–12 participants per FGD. This will take approximately 30 minutes to 1 hour per session.

Within a month after each event of the regional conversations, the last online national conversation, and the final conversations of the planned work will be held. We will develop initial themes, led by AO and BN, both of whom are experts in evaluation and are not directly involved in facilitating the conversation events. The topic guides, consent form and participant information sheet can be found as extended data.

Participants and recruitment. The evaluation participants will be the attendees of any of the project’s conversation events. Participants who attend any of the AMR Dialogues public engagement events will be invited to participate in the AMR Dialogues evaluation project. As the evaluation process is embedded in the AMR Dialogues public engagement events, participants will be asked to indicate in the registration form when attending the conversation events, whether they will allow us to record and collect information of their daily reflection, feedback in writing, group discussion and follow-up in-depth interview. Information from any participants who do not wish to participate will not be collected.

Informed consent. Participants for all conversations will be invited in writing with all relevant details. If they choose to participate in the conversations (either in person or online), they will attend the conversations.

Participants who indicated their interest for the evaluation at time of registration will receive the participant information sheet. They will be allowed as much time as they wish to consider the information, the opportunity to question the project team and to decide whether they will be willing to allow their information to be collected and recorded. At this point, they will have the opportunity to decline. If they agree to participate, they will be asked to sign and date the latest approved version of the informed consent form before any study specific procedures are performed. Depending on the circumstances (coronavirus disease 2019 (COVID-19) restrictions and geographical location/internet access), this will be done either on paper or electronically.

Each participant has the right to withdraw from the conversation events or evaluation sessions at any time. Withdrawal of consent to participate will result in exclusion of the data for that participant from analysis and withdrawn participants will not be replaced. Participants are not required to give any reason for withdrawal.

The audio recording and written data will be deleted if the participant decides to withdraw during the conversation events or the evaluation interviews. For those participating in the group discussion those portions of the audio, video recordings and written data that capture his/her views will be deleted.

Data analysis. For conversation events, meeting minutes will be taken during all conversations. The project team will reflect and refine a set of solutions and ideas that will be emerged and will inform the responsive dialogues process.

For evaluation, the qualitative data will be translated where needed, transcribed, cleaned and exported into the latest version of NVivo (© QSR International Pty Ltd), the software that will be used to manage the data. Codes will be established for each participant to enable appropriate collation of data sets and sub-themes and themes for qualitative data.

Qualitative data analysis will be based on thematic content analysis, particularly Framework Analysis, given the policy implications of the planned work. We will develop initial themes and categories through successive coding of the transcripts, and informed by the our project aims as well as issues derived from the literature. For the purpose of quality control, two researchers will independently develop their own coding tree. Frequent meetings will be held with the wider research team to discuss the findings.
Data handling and record keeping. Direct access to the data will be granted to authorised representatives from the sponsor, ethics committees, and regulatory authorities to ensure compliance with regulations. Qualitative data includes audio recordings of focus group discussion and interviews, transcripts, written feedback, meeting minutes and field notes. Audio files will be transcribed verbatim and translated to English where necessary. Detailed summary notes will be made directly following the interview and during the focus group discussion with selected verbatim quotes being used. These audio files will be kept until they have been transcribed and the transcribed interviews will be kept securely. All audio files will be destroyed when all the transcripts have been completed and verified.

De-identified data will be stored digitally and indefinitely to comply with the Wellcome Trust data sharing policies.

Ethics, quality control and quality assurance procedures
Approval of the evaluation component of the project has been obtained from the ethics committee of the Thailand Institute for the Development of Human Subject Protection (reference IHRP2021059) and the Oxford University Tropical Research Ethics Committee (OxTREC 529-21).

We will adhere to the relevant guidelines for qualitative research. All interviewers, and transcribers will be trained prior to the study. The project and its evaluation will be conducted in accordance with relevant Thai and international guidance and regulations. The protocol, informed consent form, participant information sheet and any associated material will be submitted to relevant ethics committees for written approval.

Risk and benefits
This is a minimal risk and minimal harm project. The main concerns relate to privacy and confidentiality. We will make every effort to maintain privacy of participants during the audio recording of the conversations as well as evaluation interviews and FGPs. The participants will be identified only by a participant reference number on all project documents and databases. All documents will be stored securely and only accessible by authorised study personnel. We will comply with the UK General Data Protection Regulation (GDPR) and Thailand Personal Data Protection Act (PDPA).

There are no anticipated direct benefits to the participants apart from learning about AMR and having their views heard. New knowledge gained from this initiative is expected to inform Thailand’s National Strategic Plan on Antimicrobial Resistance committee for improving policies to reduce the burden of AMR across Thailand. Participant will receive the compensation for their time to participate in the conversations (1000 Thai baht/GBP 25 per session) and evaluation focus group discussion and in-depth interviews (300 Thai baht/GBP7.5 per session).

Public involvement
This protocol describes a public involvement project. As part of the development of our study and data collection tools, we have conducted a series of meetings with the Bangkok Health Research Ethics Interest Group (BHREIG)

Dissemination of information
The learning and outcomes will be disseminated to policy makers, organisers of the Thailand AMR week, Wellcome Trust, academic audiences, as well as back to participants of all the conversation events. Some of the avenues include:

- Talks presented at conferences/meetings targeting engagement practitioners who do AMR work
- Blogs on the MESH website targeting engagement practitioners and other relevant websites
- Public talks and panel discussions conducted through MORU’s and its partners’ existing engagement channels e.g. BHREIG, science cafes, and Pint of Science events.
- Dialogues with professional groups e.g. pharmacists in Thailand and beyond, focusing on the co-created AMR solutions.
- The final AMR stakeholder map, an interim project report and final project report of the project will be provided to the Thailand’s National Strategic Plan on Antimicrobial Resistance committee.

Study status
Protocol approvals have been obtained and conversations have commenced.

Data availability
Underlying data
No data are associated with this article.

Extended data

This project contains the following extended data:
- AMR Dialogues evaluation PISICF_V3.0 21June2021.docx (participant information sheet, consent form)
- AMR Dialogues evaluation_Question guides_v3.0 21June2021.docx

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Author contributions
AO and PYC wrote the funding application for the project with significant input from TP, CT, KS, NKA, and DL. PYC, TP, RP, SR, AO, CT and KS organise and facilitate the conversation events. TP and AO are the overall project coordinators. BN leads the evaluation aspect of the project. NKA, DL, NS and SP provide input and guidance on the alignment of the project.
with the Thailand National Strategic Plan on Antimicrobial Resistance. All authors reviewed and approved the final version of the protocol. PYC is the principal investigator and the guarantor of the paper.

Acknowledgements
The authors thank members of the Bangkok Health Research Ethics Interest Group for their input in the development of the project.

References


Open Peer Review

Current Peer Review Status: ✔️

Version 1

Reviewer Report 12 October 2021

https://doi.org/10.21956/wellcomeopenres.18852.r46247

© 2021 Kaawa-Mafigiri D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David Kaawa-Mafigiri

1 Center for Social Sciences Research on AIDS, School of Social Sciences, Makerere University
College of Humanities and Social Sciences, Kampala, Uganda
2 Department of Anthropology, Case Western Reserve University, Cleveland, OH, USA

This protocol seeks to utilise an community engagement model (Dialogues with stakeholders) to influence policy making for controlling AMR in Thailand. It adopts a 'bottom-up' approach to ensure that stakeholders, particularly community members exposed to the problem participate in developing policy towards their wellbeing. It is an important contribution to the evidence on how to engage communities in solving their problems and improving their wellbeing. Specifically, for contemporary social problems like the growing epidemics of AMR, infectious disease outbreaks and other humanitarian emergencies, it is now clear that the role of non-biomedical interventions is as important in combating them, as has been the case with biomedical technology. Therefore, the authors propose a much-needed protocol to try and understand how concerned communities can be engaged and participate in shaping policies and solutions for antimicrobial resistance in Thailand.

The background, including literature on the problem of AMR in Thailand is well stated. Perhaps there may be need to expound a little more on how antibiotics and anti-inflammatory drugs are perceived or conflated in the local context. What examples of language illustrate this conflation? Expounding, with one example will enhance the background.

It was also not clear what the following statement means: “In Thailand, by law, most antimicrobials can be dispensed by licensed pharmacists at pharmacies without a prescription.” - Do you imply that it is not illegal to dispense antimicrobials without prescription? Or that the law is not followed concerning dispensing antimicrobials but when the law could be that they shouldn't be dispensed without a prescription? It may be helpful to cite the law in this case.

Objective 2 is quite important as there is a need to provide a catalyst to AMR policy while recognizing that change or improvement should be context specific and locally-driven. As such I would think that rather than ‘drive change’ the team wishes to ‘provide a catalyst for improving
current AMR policy.

The protocol is well planned. However, there are a series of activities being planned which may require a bit more elaboration on how they are tied to the or would contribute to ‘catalyzing’ change in policy. Perhaps a matrix or chart may help to tag or identify what planned meetings or sessions lie under the respective policy areas being targeted. For instance, given that there are different levels of actors whose contribution/participation is being sought, then perhaps stratifying the meetings or sessions by target populations would help the reader chart the flow of how these meetings may enhance or contribute to policy change. Similarly there were several formats of the meetings that need some clarification (e.g. would virtual breakout sessions be part of the 20-25 in-person meetings?). That is an example where it is not clear if the virtual breakout session is part of an in-person meeting such that as the in-person meeting is ongoing, there is an opportunity for the same teams to break out into sub groups but virtually?

Part 1: AMR Dialogues: Should all conversations be led by the research team? Is it possible to consider if some of the communities of participants being involved can lead some conversations – in a systematic way – without compromising on the design? Since the protocol is premised on the concept of community engagement – should the engagement entail the community leading in some of the sessions?

The study proposes sessions of 20-25 persons. Given the large numbers in the context of COVID-19, it would be good to have a note on what risk mitigation measures are in place or how those would influence/impact the method of conversation. See also the suggestion to have up to 12 participants in an FGD. What are the implications if there was COVID-19 restrictions in Thailand and how would it influence the protocol? A short note on the situation of the pandemic and how it is affecting research may help clear this. It could be elaborated under the section “risks and benefits”.

Similarly, the protocol indicates that attendees of all gender are welcome. Will age be a variable to consider and if so will it be varied or grouped and by what criteria? If not, a note on that is helpful for the reader to determine the justification or possible limitation. This comment is inspired by knowing that in some societies age determines whose opinion counts during conversations/meetings or planning for social issues.

The team plans to invite diverse stakeholders through their professional networks of previous engagement in AMR related or other health projects. Would the team comment about the issue of positionality and whether it is a potential limitation to the study?

The sample size estimation/description is not clearly stated. Are the approximately 70-85 participants for FGDs only? It may be best to simply state the number of FGDs estimated, then separately assign the number of In-depth interviews planned.

Mandatory questions:

1. Is the rationale for, and objectives of the study clearly stated?
   Partly. See further comments above under background. Objective 2 is quite important as there is a need to provide a catalyst to AMR policy while recognizing that change or improvement should be context specific and locally-driven. As such I would think that rather than ‘drive change’ the team wishes to ‘provide a catalyst for improving current AMR policy’.
2. Is the study design appropriate for the research question?
   Yes

3. Are sufficient details of the methods provided to allow replication by others?
   Yes

4. Are the datasets clearly presented in a usable and accessible format?
   Yes

**Is the rationale for, and objectives of, the study clearly described?**
Partly

**Is the study design appropriate for the research question?**
Yes

**Are sufficient details of the methods provided to allow replication by others?**
Yes

**Are the datasets clearly presented in a useable and accessible format?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Medical Anthropology, infectious disease control, community based interventions

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Comments on this article**

**Version 1**

Reader Comment 09 Aug 2021

**Ahmad Akbar Jaya Sapie**, MedHEU, Malaysia

1. AMR is a sub-topic of One Health, address the need ensuring safe ecosystem of antimicrobial usage.

2. Interested in community engagement. This means empower and making them responsible to deal with AMR. Furthermore, the community involved are various from different level of background which is good in defining appropriate policies.
3. Informed consent - How it was conducted in proper way gives confident to the result? Participants can withdraw whenever they want respect autonomy and dignity.

Questions:

For data handling, should we decide how long it will be kept after transcribed? And can it be used repeatedly for another objectives which is related to the study, however do not mentioned at the informed consent at the first place?

Do researchers need to includes an appendix of what questions involved in the FDG and depth interview for Ethics Member to review?

**Competing Interests:** No competing interests were disclosed.